clinical trial · NCT06767683
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.·phase3·recruiting·n = 256
Narcolepsy Type 1Narcolepsy Type 2Idiopathic HypersomniaALKS 2680, 4mgALKS 2680, 6mgALKS 2680, 8mgALKS 2680, 10mgALKS 2680, 14mgALKS 2680, 18mg
brief summary
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
started
Jan 27, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Mar 4, 2026
official title
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol